Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Swiech, Kamilla ^a   Kamen, Amine ^b   Ansorge, Sven ^b   Durocher, Yves ^b   Picanço Castro, Virgínia ^a   Russo Carbolante, Elisa M S ^a   Neto, Mário S A ^a   Covas, Dimas T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEEDING DISORDER; COAGULATION FACTOR; DNA CONCENTRATION; EFFICIENT PRODUCTION; FACTOR VIII; HEK293 CELLS; HEMOPHILIA A; HIGH PRICE; PRODUCT SHORTAGES; TRANSFECTION EFFICIENCY; TRANSIENT TRANSFECTION;

ANIMAL CELL CULTURE; BODY FLUIDS; CELLS; COAGULATION; SUSPENSIONS (FLUIDS);

MOLECULAR BIOLOGY;

DNA; POLYETHYLENEIMINE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; CELL DENSITY; CELL GROWTH; CELL STRAIN HEK293; CELL VIABILITY; CULTURE MEDIUM; GENETIC TRANSFECTION; NUCLEOTIDE SEQUENCE; NUTRIENT UPTAKE; TEMPERATURE SENSITIVITY;

AMMONIA; BIOTECHNOLOGY; BLOOD CELL COUNT; CELL CULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERYTHROSINE; FACTOR VIII; GLUCOSE; HEK293 CELLS; HUMANS; LACTIC ACID; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 82055163895     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-114     Document Type: Article

References (51)

1. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnology Journal 2009, 4:186-201. 10.1002/biot.200800241, 2699044, 19226552.
2. Lynch CM, Israel DI, Kaufman RJ, Miller AD. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993, 4:259-272. 10.1089/hum.1993.4.3-259, 8338874.
3. Kolind MP, Norby PL, Flintegaard TV, Berchtold MW, Johnsen LB. The B-domain of factor VIII reduces cell membrane attachment to host cells under serum free conditions. Journal of Biotechnology 2010, 147:198-204. 10.1016/j.jbiotec.2010.04.010, 20438774.
4. Spencer HT, Denning G, Gautney RE, Dropulic B, Roy AJ, Baranyi L, Gangadharan B, Parker ET, Lollar P, Doering CB. Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII. Molecular Therapy 2011, 19:302-309. 10.1038/mt.2010.239, 21081907.
5. Dorner AJ, Bole DG, Kaufman RJ. The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins. J Cell Biol 1987, 105:2665-2674. 10.1083/jcb.105.6.2665, 2114744, 3121636.
6. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989, 9:1233-1242. 362714, 2498645.
7. Kaufman RJ. Expression and structure-function properties of recombinant factor VIII. Transfusion Medicine Reviews 1992, 6:235-246. 10.1016/S0887-7963(92)70174-6, 1421822.
8. Kaufman RJ, Pipe SW, Tagliavacca L, Swaroop M, Moussalli M. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 1997, 8(Suppl 2):S3-14.
9. Miao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004, 103:3412-3419. 10.1182/blood-2003-10-3591, 14726380.
10. Lynch TJ. Biotechnology: alternatives to human plasma-derived therapeutic proteins. Baillieres's Clinical Haematology 2000, 13:669-688.
11. Garber K. rFactor VIII deficit questioned. Nature Biotechnology 2000, 18:1133. 10.1038/81098, 11062420.
12. Pham PL, Perret S, Doan HC, Cass B, St-Laurent G, Kamen A, Durocher Y. Large-scale transfection of serum-free suspension-growing HEK293 EBNA1 cells: peptone additives improve cell growth and transfection efficiency. Biotechnol Bioeng 2003, 84:332-342. 10.1002/bit.10774, 12968287.
13. Pham PL, Kamen A, Durocher Y. Large scale transfection of mammalian cells for the fast production of recombinant protein. Molecular Biotechnology 2006, 34:225-237. 10.1385/MB:34:2:225, 17172668.
14. Côté J, Garnier A, Massie B, Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 1998, 59:567-575. 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.0.CO;2-8, 10099373.
15. Tonn T, Herder C, Becker S, Seifried E, Grez M. Generation and Characterization of Human Hematopoietic Cell Lines Expressing Factor VIII. Journal of Hematotherapy & Stem Cell Research 2002, 11(4):695-704. 10.1089/15258160260194848, 10417055.
16. Tom R, Bisson L, Durocher Y. Transient expression in HEK293-EBNA1 cells. Methods Express: Expression Systems 2007, 203-223. Oxfordshire: Scion Publishing Ltd, Dyson MR, Durocher Y.
17. Sun X, Hia HC, Goh PE, Yap GS. High-density transient gene expression in suspension-adapted 293 EBNA1 cells. Biotechnology and Bioengineering 2008, 99:108-116. 10.1002/bit.21537, 17630648.
18. Durocher Y, Perret S, Kamen A. High-level and hogh-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002, 30:E9. 10.1093/nar/30.2.e9, 99848, 11788735.
19. Ansorge S, Lanthier S, Transfiguracion J, Durocher Y, Henry O, Kamen A. Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J Gene Med 2009, 11:868-76. 10.1002/jgm.1370, 19618482.
20. Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol 1994, 68(Suppl 3):S9-14.
21. Winge S. Method for isolation of recombinantly produced proteins. 2006, International Application No.: PCT/EP2006/061148. Pub. No.: WO/2006/103258.
22. Sunley K, Butler M. Strategies for the enhancement of recombinant protein production from mammalian cells by growth arrest. Biotechnology Advances 2010, 28:385-394. 10.1016/j.biotechadv.2010.02.003, 20156545.
23. Rieder CL, Cole RW. Cold shock and the mammalian cell cycle. Cell Cycle 2002, 1:169-175.
24. Yoon SK, Song JY, Lee GM. Effect of low culture temperature on specific productivity, transcription level, and heterogeneity of erythropoietin in Chinese hamster ovary cells. Biotechnol Bioeng 2003, 82:289-98. 10.1002/bit.10566, 12599255.
25. Jorjani P, Ozturk SS. Effects of cell density and temperature on oxygen consumption rate for different mammalian cell lines. Biotechnol Bioeng 1999, 64:349-356. 10.1002/(SICI)1097-0290(19990805)64:3<349::AID-BIT11>3.0.CO;2-V, 10397872.
26. Rodriguez J, Spearman M, Huzel N, Butler M. Enhanced production of monomeric interferon-β by CHO cells through the control of culture conditions. Biotechnology Progress 2005, 21:22-30.
27. Oguchi S, Saito H, Tsukahara M, Tsumura H. pH Condition in temperature shift cultivation enhances cell longevity and specific hMab productivity in CHO culture. Cytotechnology 2006, 52:199-207.
28. Yoon SK, Choi SL, Song JY, Lee GM. Effect of culture pH on erythropoietin production by Chinese hamster ovary cells grown in suspension at 32.5 and 37.0 degrees C. Biotechnol Bioeng 2005, 89:345-56. 10.1002/bit.20353, 15625678.
29. Moore A, Mercer J, Dutina G, Donahue CJ, Bauer KD, Mather JP, Etcheverry T, Ryll T. Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch cultures. Cytotechnology 1997, 23:47-54.
30. Sakurai T, Itoh K, Liu Y, Higashitsuji H, Sumitomo Y, Sakamaki K, Fujita J. Low temperature protects mammalian cells from apoptosis initiated by various stimuli in vitro. Exp Cell Res 2005, 309:264-72. 10.1016/j.yexcr.2005.06.002, 16018998.
31. Ahn M-H, Song M, Oh E-Y, Jamal A, Kim H, Ko K, Choo Y-K, Kim B-J, Ko K. Production of therapeutic proteins with baculovirus expression system in insect cell. Entomological Research 2008, 38:S71-S78.
32. Haack A, Schmitt C, Poller W, Oldenburg J, Hanfland P, Brackmann HH, Schwaab R. Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell lines. Annals of Hematology 1998, 78:111-116.
33. Chen C, Fang XD, Zhu J, Wu XF, Zhang ZC, Gu JX, Wang ZY, Chi CW. The Gene Expression of Coagulation Factor VIII in Mammalian Cell Lines. Thrombosis Research 1999, 95:105-115. 10.1016/S0049-3848(99)00031-6, 10418799.
34. Cho MS, Yee H, Brown C, Mei B, Mirenda C, Chan S. Versatile expression system for rapid and stable production of recombinant proteins. Biotechnology Progress 2003, 19:229-232. 10.1021/bp0255964, 12573030.
35. Mei B, Chen Y, Chen J, Pan CQ, Murphy JE. Expression of human coagulation factor VIII in a human hybrid cell line, HKB11. Molecular Biotechnology 2006, 34:165-178. 10.1385/MB:34:2:165, 17172662.
36. Campos-da-Paz M, Costa CS, Quilici LS, Simões IC, Kyaw CM, Maranhão AQ, Brigido MM. Production of Recombinant Human Factor VIII in Different Cell Lines and the Effect of Human XBP1 Co-Expression. Molecular Biotechnology 2008, 39:155-158. 10.1007/s12033-008-9055-6, 18327549.
37. Picanco-Castro V, Russo-Carbolante EMS, Fontes AM, Fernandes AC, Covas DT. An enhancer/promoter combination strengthens the expression of blood-coagulation factor VIII in non-viral expression vectors. Genetics and Molecular Research 2008, 7:314-325. 10.4238/vol7-2gmr447, 18551397.
38. Baru M, Carmel-Goren L, Barenholz Y, Dayan I, Ostropolets S, Slepoy I, Gvirtzer N, Fukson V, Spira J. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy. Thrombosis and Haemostasis 2005, 93:1061-1068.
39. Lillicrap D. Extending half-life in coagulation factors: where do we stand?. Thrombosis Research 2008, 122:S2-S8.
40. Wakabayashi H, Varfaj F, DeAngelis J, Fay PJ. Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Hemostasis, Thrombosis, and Vascular Biology 2008, 112:2761-2769.
41. Roy S, Shirley S, Connelly S, Andrews JL, Kayda DB, Gardner JM, Kaleko M. In vivo evaluation of a novel epitope-tagged human factor VIII-encoding adenoviral vector. Haemophilia 1999, 5:340-348. 10.1046/j.1365-2516.1999.00310.x, 10583516.
42. Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem HP, Ganser A, Scherr M. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Therapy 2003, 10:1917-1925. 10.1038/sj.gt.3302093, 14502221.
43. Herder C, Tonn T, Oostendorp R, Becker S, Keller U, Peschel C, Grez M, Seifried E. Sustained expansion and transgene expression of coagulation factor VIII-transduced cord blood-derived endothelial progenitor cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23:2266-2272. 10.1161/01.ATV.0000100403.78731.9F, 14551158.
44. Matsui H, Shibata M, Brown B, Labelle A, Hegadorn C, Andrews C, Hebbel RP, Galipeau J, Hough C, Lillicrap D. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007, 25:2660-2669. 10.1634/stemcells.2006-0699, 17615271.
45. Kasuda S, Kubos A, Sakurai Y, Irion S, Ohashi K, Tatsumi K, Nakajiwa Y, Saito Y, Hatake K, Pipe SW, Shima M, Yoshioka A. Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A. Journal of Thrombosis and Haemostasis 2008, 6:1352-1359. 10.1111/j.1538-7836.2008.03022.x, 18485084.
46. Baldi L, Hacker DL, Adam M, Wurm FM. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 2007, 29:677-684. 10.1007/s10529-006-9297-y, 17235486.
47. Rozkov A, Larsson B, Gillstrom S, Bjornestedt R, Schmidt SR. Large-scale production of endotoxin-free plasmids for transient expression in mammalian cell culture. Biotechnology and Bioengineering 2008, 99:557-566. 10.1002/bit.21603, 17680665.
48. Wright JL, Jordan M, Wurm FM. Transfection of partially purified plasmid DNA for high level transient protein expression in HEK293-EBNA cells. Journal of Biotechnology 2003, 102:211-221. 10.1016/S0168-1656(03)00032-4, 12730010.
49. Cheng L, Sun X, Yi X, Zhang Y. Large-scale plasmid preparation for transient gene expression. Biotechnology Letters 2011, 33:1559-1564. 10.1007/s10529-011-0612-x, 21476094.
50. Schorr J, Moritz P, Breul A, Scheef M. Production of plasmid DNA in industrial quantities according to cGMP guidelines. Methods Mol Med 2006, 127:339-50.
51. Geisse S. Reflections on more than 10 years of TGE approaches. Protein Expression and Purification 2009, 64:99-107. 10.1016/j.pep.2008.10.017, 19027070.